Vincent Perrone | Senior Director, IR |
Elizabeth Barrett | President, CEO & Director |
Mark Schoenberg | Chief Medical Officer |
Jeffrey Bova | Chief Commercial Officer |
Dong Kim | CFO |
Christopher Howerton | Jefferies |
Raghuram Selvaraju | H.C. Wainwright & Co. |
Boris Peaker | Cowen and Company |
Matthew Kaplan | Ladenburg Thalmann & Co. |
Leland Gershell | Oppenheimer |
Ladies and gentlemen, thank you for standing by, and welcome to the UroGen Pharma second quarter 2022 update conference call. It's my pleasure to hand the call over to Vincent Perrone, Senior Director of Investor Relations for your [Technical Difficulty]. Please go ahead.
Thank you, operator. Good morning, everyone.